Core Viewpoint - The stock of Sihuan Pharmaceutical (00460) has risen over 9%, currently trading at 1.54 HKD with a transaction volume of 113 million HKD, following the acceptance of a listing application for Semaglutide injection by the National Medical Products Administration (NMPA) [1] Group 1: Company Developments - Sihuan Pharmaceutical's subsidiary, Huisheng Biopharmaceutical Co., Ltd., has received acceptance for the listing application of Semaglutide injection, aimed at improving blood sugar control in adult patients with type 2 diabetes [1] - The indication for weight loss using Semaglutide injection has completed Phase III clinical enrollment and is currently in the follow-up stage [1] - The diabetes sector is a key focus area for Huisheng Biopharmaceutical, and the acceptance of the listing application represents a significant advancement in the drug's development process, enhancing the company's core competitiveness in diabetes treatment [1]
四环医药涨超9% 惠升生物旗下司美格鲁肽注射液上市申请获国家药监局受理